Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Results of an open label feasibility study of sodium valproate in people with McArdle disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. 251st ENMC international workshop: Polyglucosan storage myopathies 13-15 December 2019, Hoofddorp, the Netherlands

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Contractile properties are impaired in congenital myopathies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Habitual Physical Activity in Patients with Myasthenia Gravis Assessed by Accelerometry and Questionnaire

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Muscle biopsy and MRI findings in ANO5-related myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

McArdle disease results from a lack of muscle glycogen phosphorylase in skeletal muscle tissue. Regenerating skeletal muscle fibres can express the brain glycogen phosphorylase isoenzyme. Stimulating expression of this enzyme could be a therapeutic strategy. Animal model studies indicate that sodium valproate (VPA) can increase expression of phosphorylase in skeletal muscle affected with McArdle disease. This study was designed to assess whether VPA can modify expression of brain phosphorylase isoenzyme in people with McArdle disease. This phase II, open label, feasibility pilot study to assess efficacy of six months treatment with VPA (20 mg/kg/day) included 16 people with McArdle disease. Primary outcome assessed changes in VO2peak during an incremental cycle test. Secondary outcomes included: phosphorylase enzyme expression in post-treatment muscle biopsy, total distance walked in 12 min, plasma lactate change (forearm exercise test) and quality of life (SF36). Safety parameters. 14 participants completed the trial, VPA treatment was well tolerated; weight gain was the most frequently reported drug-related adverse event. There was no clinically meaningful change in any of the primary or secondary outcome measures including: VO2peak, 12 min walk test and muscle biopsy to look for a change in the number of phosphorylase positive fibres between baseline and 6 months of treatment. Although this was a small open label feasibility study, it suggests that a larger randomised controlled study of VPA, may not be worthwhile.

OriginalsprogEngelsk
TidsskriftNeuromuscular disorders : NMD
Vol/bind30
Udgave nummer9
Sider (fra-til)734-741
Antal sider8
ISSN0960-8966
DOI
StatusUdgivet - sep. 2020

Bibliografisk note

Copyright © 2020 Elsevier B.V. All rights reserved.

ID: 61071630